This special issue of Endoscopy is dedicated to the subject of total Barrett eradication, that is the complete removal of Barrett esophagus and asso− ciated neoplasia by endoscopic resection and/or endoscopic ablation techniques. Many leading experts in the field have contributed to this im− portant issue. Drs. Shaheen and Spechler discuss the relevant methodological issues and pitfalls in studies of Barrett esophagus eradication [1], Drs. Curvers and Bansal offer recommendations for the endoscopic work−up of patients with Barrett esophagus−related neoplasia (BERN) [2] , and Drs. Odze and Lauwers clearly describe how pre− and post−treatment histology should be evaluat− ed [3] . Subsequently, leaders in the field of thera− peutic endoscopy discuss the different available endoscopic treatment modalities for BERN: en− doscopic resection, argon plasma coagulation (APC), cryotherapy, photodynamic therapy (PDT), and radiofrequency ablation (RFA) [4 ± 7]. Finally, Drs. Peters [8] and Falk [9] look into the crystal ball to predict the future of endoscopic treatment of BERN from a surgeon's and an en− doscopist's viewpoint, respectively. Why has a special issue of Endoscopy been dedi− cated to this topic? The evidence is now accumu− lating that endoscopic treatment of BERN is safe and effective, suggesting that this approach should be preferred over esophagectomy in se− lected patients [10 ± 12]. New endoscopic tools, most recently endoscopic resection and RFA, ap− pear to be effective not only in removing BERN but also in completely eradicating all associated Barrett mucosa in the majority of treated patients [13 ± 16]. As a result, many expert centers have adopted advanced imaging, endoscopic resec− tion, and ablation as their management strategy for BERN. In our opinion, the past five years have yielded a number of very promising advances for our field in the endoscopic diagnosis, staging, and man− agement of BERN. We have moved from an era of "survey most lesions and operate on those with high grade dysplasia and cancer," to an era where we have the option to "survey all lesions, endoscopically treat selected lesions, and reserve surgery only for patients with invasive cancers involving the submucosa." We are witnessing a significant paradigm shift ± one that is accompa− nied by new challenges that we must be prepared to address. These challenges include: maintain− ing technical excellence and safety with all pro− cedures, via robust training programs; ensuring that visible lesions are detected and properly staged prior to initiation of an endoscopic treat− ment regimen; preparing the patient for endo− scopic management; evaluating the evidence cri− tically to determine ideal patient selection crite− ria, and which disease states should be treated; and evaluating the financial realities of cost−ef− fectiveness and reimbursement. Regarding technical excellence, endoscopic re− section and ablative therapies for BERN generally encompass multiple endoscopic modalities for diagnosis, staging, and treatment. Done properly, we believe they are highly effective and quite safe for the patient. We need to develop training pro− grams for physicians and our advanced trainees so that currently reported efficacy and safety pro− files are maintained. Extracurricular training courses (see www.endosurgery.eu for examples) aimed at the entire spectrum of endoscopic man− agement are being developed to achieve these objectives. Endoscopic detection and proper staging of pa− tients with BERN prior to therapy, are essential. Most available studies come from expert centers with standardized endoscopic staging algo− rithms, high quality therapeutic interventions, rigorous endoscopic follow−up, and expert histo− pathological evaluation. Respectfully, a general endoscopist may not see as many cases of BERN as endoscopists in expert centers and therefore may not be as likely to recognize the subtle 
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This special issue of Endoscopy is dedicated to the subject of total Barrett eradication, that is the complete removal of Barrett esophagus and asso− ciated neoplasia by endoscopic resection and/or endoscopic ablation techniques. Many leading experts in the field have contributed to this im− portant issue. Drs. Shaheen and Spechler discuss the relevant methodological issues and pitfalls in studies of Barrett esophagus eradication [1] , Drs. Curvers and Bansal offer recommendations for the endoscopic work−up of patients with Barrett esophagus−related neoplasia (BERN) [2] , and Drs. Odze and Lauwers clearly describe how pre− and post−treatment histology should be evaluat− ed [3] . Subsequently, leaders in the field of thera− peutic endoscopy discuss the different available endoscopic treatment modalities for BERN: en− doscopic resection, argon plasma coagulation (APC), cryotherapy, photodynamic therapy (PDT), and radiofrequency ablation (RFA) [4 ± 7] . Finally, Drs. Peters [8] and Falk [9] look into the crystal ball to predict the future of endoscopic treatment of BERN from a surgeon's and an en− doscopist's viewpoint, respectively. Why has a special issue of Endoscopy been dedi− cated to this topic? The evidence is now accumu− lating that endoscopic treatment of BERN is safe and effective, suggesting that this approach should be preferred over esophagectomy in se− lected patients [10 ± 12] . New endoscopic tools, most recently endoscopic resection and RFA, ap− pear to be effective not only in removing BERN but also in completely eradicating all associated Barrett mucosa in the majority of treated patients [13 ± 16] . As a result, many expert centers have adopted advanced imaging, endoscopic resec− tion, and ablation as their management strategy for BERN. In our opinion, the past five years have yielded a number of very promising advances for our field in the endoscopic diagnosis, staging, and man− agement of BERN. We have moved from an era of "survey most lesions and operate on those with high grade dysplasia and cancer," to an era where we have the option to "survey all lesions, endoscopically treat selected lesions, and reserve surgery only for patients with invasive cancers involving the submucosa." We are witnessing a significant paradigm shift ± one that is accompa− nied by new challenges that we must be prepared to address. These challenges include: maintain− ing technical excellence and safety with all pro− cedures, via robust training programs; ensuring that visible lesions are detected and properly staged prior to initiation of an endoscopic treat− ment regimen; preparing the patient for endo− scopic management; evaluating the evidence cri− tically to determine ideal patient selection crite− ria, and which disease states should be treated; and evaluating the financial realities of cost−ef− fectiveness and reimbursement. Regarding technical excellence, endoscopic re− section and ablative therapies for BERN generally encompass multiple endoscopic modalities for diagnosis, staging, and treatment. Done properly, we believe they are highly effective and quite safe for the patient. We need to develop training pro− grams for physicians and our advanced trainees so that currently reported efficacy and safety pro− files are maintained. Extracurricular training courses (see www.endosurgery.eu for examples) aimed at the entire spectrum of endoscopic man− agement are being developed to achieve these objectives. Endoscopic detection and proper staging of pa− tients with BERN prior to therapy, are essential. Most available studies come from expert centers with standardized endoscopic staging algo− rithms, high quality therapeutic interventions, rigorous endoscopic follow−up, and expert histo− pathological evaluation. Respectfully, a general endoscopist may not see as many cases of BERN as endoscopists in expert centers and therefore may not be as likely to recognize the subtle changes that accompany early neoplastic alteration in Barrett esophagus. With the current quality of white light endoscopy, our eyes have become the weakest link in the detection chain [17] . The International Working Group for Classification of Oeso− phagitis (www.iwgco.org), the same group that developed and validated the Los Angeles (LA) classification for erosive esopha− gitis and the Prague circumferential and maximal (C&M) criteria for grading the extent of Barrett esophagus [18] , is currently working on teaching materials to aid in the standardization of BERN recognition. All the experts involved in this issue of Endos− copy agree that endoscopic resection is a cornerstone for endo− scopic management of BERN since it allows histological correla− tion thus enabling optimal patient selection. Patients with sub− mucosal invasion should be referred for surgery because they have a 15 % ± 30 % risk of positive local lymph nodes whereas this risk is minimal in patients with intramucosal cancer or high grade intraepithelial neoplasia (HGIN) [19] . The patient must be prepared for an intense regimen of endo− scopic staging, treatment, and continued surveillance, as a num− ber of endoscopic procedures may be required before complete eradication of Barrett esophagus has been achieved and the pa− tient allowed to re−enter a possibly modified surveillance pro− gram. One or two mapping procedures are generally required be− fore an endoscopic resection is performed [20] . After healing of the endoscopic resection site most patients require multiple ab− lation sessions (median 3) performed at 2−month intervals [13 ± 16] . Even then, approximately 10 % ± 15 % of patients may require an endoscopic resection as an "escape treatment" for complete removal of all Barrett mucosa [13, 14] . The impressive success rates recently reported thus require between five and nine endo− scopic procedures and the endoscopic work−up and treatment may cover a period of 12 to 15 months. The psychological impact of such a prolonged endoscopic treatment on patients is prob− ably underestimated. Certainly, the surgical alternative is more expensive, more risky and more demanding for patients. Never− theless, we need to improve the practicality of our current algo− rithms for endoscopic management of BERN and not close our eyes to the negative psychological impact of being treated for a stigmatizing disease such as esophageal cancer. Which patients with Barrett esophagus should be offered endo− scopic treatment? The progress made in this field is possibly best illustrated by the fact that discussions about who should be treated have moved away from BERN, with endoscopic ther− apy now accepted as the treatment of choice for that condition, to debate about the treatment of non−neoplastic Barrett esopha− gus. This debate is fuelled by the controversies relating to life− long endoscopic surveillance of Barrett esophagus (cost−effec− tiveness, negative impact on the quality of life of patients) and the promising results of recent RFA studies. RFA appears to have many of the features of an ideal ablation technique. Its reported efficacy and safety profile is impressive in a range of study de− signs [7] , the neosquamous mucosa that develops after the abla− tion has been shown to be free of genetic abnormalities [21] , and the occurrence of residual areas of columnar mucosa under− neath the neosquamous mucosa ("buried Barrett's") is found to be extremely low [13 ± 16] . Recent cost−effectiveness data in− deed suggest that complete eradication of non−neoplastic Bar− rett esophagus is more cost−effective than lifelong surveillance [22] . Despite these promising results, we believe that it is too early to broadly embrace RFA for treating patients with non−neo− plastic Barrett esophagus [23] . Compared with patients with BERN, patients with non−neoplastic Barrett esophagus have a lower rate of progression to adenocarcinoma (approximately 0.5 % per patient per year of follow−up). Longer follow−up is re− quired to show that complete eradication actually persists and to prove that endoscopic surveillance of these patients indeed can be stopped once total Barrett eradication has been achieved. All the largest published prospective series on RFA in Barrett esophagus have included fewer than 150 patients. Although these have all shown absence of severe complications and esophageal scarring, studies on a larger scale are necessary to provide reliable point estimates for rare complications. Treat− ment of this patient group should therefore only be considered in the setting of a prospective registry or clinical trial, with the informed consent of patients, to allow collection of long−term safety and efficacy data on a wide scale. Finally, we need to consider the economics of endoscopic man− agement for BERN. Several decision analyses have shown that surveillance for BERN is not cost−effective because of recurring lifelong costs related to endoscopy and biopsy, plus the potential for cancer progression. Recent studies have also shown that en− doscopic therapy (PDT and RFA) is more cost−effective than sur− gery and even surveillance for BERN [24] . We must consider this evidence in light of the fact that endoscopic management for BERN might be cost−effective but it is simultaneously resource− intensive, like surveillance and surgery, and it might not (yet) be adequately reimbursed for all patients by third−party payers, de− pending on the region. If the scientific evidence supports endo− scopic management, we should be prepared to perform the stud− ies and do the work necessary to support payment for services for those patients that we deem eligible for treatment. Selecting the right patient, accurately grading and staging the Barrett segment, and access to expertise in pathology and endos− copy ± these form the ingredients for achieving complete Barrett eradication. We hope that you will find this special issue of En− doscopy useful and informative for managing your patients with BERN.
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